Portal de Periódicos da CAPES

LOW MORTALITY FROM COVID‐19 IN PATIENTS WITH B CELL LYMPHOMA AFTER BISPECIFIC CD3 X CD20 THERAPY

2023; Wiley; Volume: 41; Issue: S2 Linguagem: Inglês

10.1002/hon.3165_663

1099-1069

Emil Ramsø Kyvsgaard, Christopher B. Riley, Michael Roost Clausen, L. D. Heftdal, Carsten Utoft Niemann, K. Grønbæk, Martin Hutchings, Simon Husby,

SARS-CoV-2 and COVID-19 Research

Introduction: Patients with hematological malignancies are at an increased risk of morbidity and mortality from COVID-19. Especially patients treated with CAR-T cell therapy for B-cell malignancies have poor outcomes after COVID-19, with case mortality rates >40%. Outcomes of COVID-19 in patients treated with CD20xCD3 bispecific antibodies have not been reported. Methods: We identified all patients treated with bispecific antibodies in Denmark from December 2019 to December 2022. We collected data on date and variant of positive SARS-CoV-2 PCR tests, symptoms, reactivations, resolution of disease (either clinical, confirmed by negative PCR test or at death), vaccination status and treatments using electronic health charts and national registries. We assessed time from infection to death, reactivation or resolution and used a univariable cox regression to assess risk factors of reactivation of COVID-19. Results: Of 130 treated patients we identified 43 patients infected with SARS-CoV-2, 5 were infected prior to CD20xCD3 treatment, and 38 were infected during CD20xCD3 treatment or after end-of-treatment. Five out of thirty-eight patients infected with SARS-CoV-2 died, but only in two patients was death related to COVID-19. The resulting COVID-19 attributable case mortality rate was thus 5.2% (95% CI 1,5% to 17.3%, Figure 1), while overall mortality was 13.2% (95%CI 5,75% to 27,3%) with a median follow-up of 11.2 months. Of the 5 patients who died during follow-up, 4 had refractory/relapsed lymphoma, at the time of the first infection with SARS-COV-2. Data on SARS-CoV-2 variants were available in 21 patients, whereof 19 were infected with omicron and 2 patients with delta. Seventeen out of thirty-eight patients had at least one reactivation of COVID-19. The mean number of reactivations was 2.9 (95%CI 1.5 to 4.3), ranging from 1 up to 9. In univariable Cox regression, the significant factors associated with reactivation were hospitalization during the first SARS-CoV-2 infection and prior treatment with bendamustine (HR: 4.36, 95%CI 1.47-12.9, p=0.008 and HR: 4.68, 95%CI 1.63-13.5, p=0.004, respectively). The median time to clinical resolution of COVID-19 was 13.5 days (IQR: 9) and the median time to virologic (PCR) resolution was 66 days (IQR: 52). The research was funded by: The project was supported by grants from Rigshospitalets Research foundation, "Sejer perssons og Lis Klüver Perssons legat" and "Frk. Amalie Jørgenens legat". Keywords: Aggressive B-cell non-Hodgkin lymphoma, Immunotherapy, Late Effects in Lymphoma Survivors No conflicts of interests pertinent to the abstract to be declared.